SEASTAR MEDICAL HOLDING CORPORATION - COMMON STOCK

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

22 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

18 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

08 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

25 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt

04 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update

13 Aug 2024 15:38:00 By Nasdaq GlobeNewswire

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device

23 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial

16 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner

12 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

11 Jul 2024 15:05:00 By Nasdaq GlobeNewswire